Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib combined with chemoradiotherapy for first-line treatment of advanced esophageal squamous cell carcinoma (real-world study)
ChiCTR2000041182Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Wannan Medical College
- Start
- Dec 2020
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The First Affiliated Hospital of Wannan Medical College. Primary endpoint: Progression-free survival. Started Dec 2020; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2000041182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041182.